notoginsenoside Fc: a platelet aggregation inhibitor; isolated from Panax notoginseng; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Panax | genus | An araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH] | Araliaceae | The ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 75412556 |
| MeSH ID | M000612884 |
| Synonym |
|---|
| notoginsenoside fc |
| 88122-52-5 |
| AKOS030530158 |
| HY-N2531 |
| CS-0022802 |
| notoginsenosidefc |
| MS-32053 |
| AC-34758 |
| DTXSID301316021 |
Notoginsenoside Fc (NGFc) is a protopanaxadiol-type (PPD-type) saponin from Panax notoginseng. It has perfect anti-platelet aggregatory effect.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Notoginsenoside Fc, which is a protopanaxdiol-type saponin isolated from the leaves of Panax notoginseng, exhibits an exceptional antiplatelet aggregatory effect. " | ( Identification and quantitative investigation of the effects of intestinal microflora on the metabolism and pharmacokinetics of notoginsenoside Fc assayed by liquid chromatography with electrospray ionization tandem mass spectrometry. Ju, Z; Li, J; Lu, Q; Wang, Z; Yang, L; Yang, Y, 2019) | 2.16 |
| "Notoginsenoside Fc (NGFc) is a protopanaxadiol-type (PPD-type) saponin from Panax notoginseng, which has perfect anti-platelet aggregatory effect. " | ( Pharmacokinetics, bioavailability, and metabolism of Notoginsenoside Fc in rats by liquid chromatography/electrospray ionization tandem mass spectrometry. He, C; Li, J; Li, Z; Wang, R; Wang, Z; Xu, N; Yang, L, 2015) | 2.11 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The validated LC-MS/MS method was successfully applied to the pre-clinical pharmacokinetic studies of NGFc in rat." | ( Pharmacokinetics, bioavailability, and metabolism of Notoginsenoside Fc in rats by liquid chromatography/electrospray ionization tandem mass spectrometry. He, C; Li, J; Li, Z; Wang, R; Wang, Z; Xu, N; Yang, L, 2015) | 0.67 |
| " Through an in vivo pharmacokinetic study, the pharmacokinetic characteristics were compared between normal rats and pseudo germ-free rats." | ( Identification and quantitative investigation of the effects of intestinal microflora on the metabolism and pharmacokinetics of notoginsenoside Fc assayed by liquid chromatography with electrospray ionization tandem mass spectrometry. Ju, Z; Li, J; Lu, Q; Wang, Z; Yang, L; Yang, Y, 2019) | 0.72 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.32) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||